It is concluded that precision medicine in RA will require integrated biomarker panels combining clinical, pharmacological, molecular, and synovial tissue data, and the development of scalable, externally validated, and clinically interpretable models capable of assigning synovial endotypes and supporting mechanism-based therapeutic selection.
N. A. Batashkov, E. Gerasimova, D. Gerasimova et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.